MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Zamicastat

CAS No. : 1080028-80-3

MCE 站：Zamicastat

产品活性：Zamicastat (BIA 5-1058) 是多巴胺 β-羟化酶 (DBH) 抑制剂，可透过血脑屏障引起中枢和周边效应。Zamicastat 也是一种浓度依赖性的双重 P-gp 和 BCRP 抑制剂，IC₅₀ 值分别为 73.8 μM 和 17.0 μM。Zamicastat 具有降血压作用。

研究领域：Metabolic Enzyme/Protease  |  Membrane Transporter/Ion Channel

作用靶点：Dopamine β-hydroxylase  |  P-glycoprotein  |  BCRP

In Vitro: Following 4 hours of incubation (5, 10, 20, 50, 80, 100 μM), a significant loss of cell viability is verified with 100 μM Zamicastat (p=0.010) in MDCK-BCRP cells. No significant losses of cell viability are observed after 4 h of incubation for other concentrations in all cell lines. By decreasing the incubation period to 30 min, there is no significant loss of cell viability (p>0.05) at 100 μM in all cell lines.

In Vivo: Zamicastat (10, 30 ａnd 100 mg/kg/day; oral bolus, 7 days) is tested acutely against salt-induced hypertension in the Dahl SS rat. Zamicastat produces a dose-dependent decrease in blood pressure. 24 h after Zamicastat administration mean systolic blood pressure (SBP) decrease is -12.6±4.1 mm Hg (P=0.0284), -15.2±2.7 mm Hg (P=0.0026) ａnd -19.0±3.7 mm Hg (P=0.0036) for the 10, 30, ａnd 100 mg/kg body weight dose, respectively. Zamicastat administration also produces a significant 24-h average decrease in diastolic blood pressure (DBP) of - 14.6±3.4 mm Hg (P=0.0073) with 10 mg/kg body weight dose, -13.0±4.5 mm Hg (P=0.0347) with 30 mg/kg body weight dose ａnd -15.0±3.1 mm Hg (P=0.0046) with 100 mg/kg body weight dose. Zamicastat administration leads to a decrease in the 24h post-dose mean arterial pressure (MAP) of -13.4±3.8 mm Hg (P=0.0162), -14.0±3.5 mm Hg (P=0.0101) ａnd -20.6±3.7 mm Hg (P=0.0026) for the 10, 30, ａnd 100 mg/kg body weight dose, respectively. There is a small, but significant, effect of Zamicastat on the 24-h mean heart rate (HR) post-dose for all tested doses (10 mg/kg: -19.1±3.2 beats/min, P=0.0019; 30 mg/kg: -13.0±4.5 beats/min, P=0.0347; 100 mg/kg: -21.6±6.6 beats/min, P=0.0235).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Metabolism/Protease Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Orally Active Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Cancer Stem Cells Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Biricodar  |  Hypericin  |  PCI 29732  |  Trifluoperazine dihydrochloride  |  Atazanavir  |  Sinapine thiocyanate  |  Dofequidar fumarate  |  AZD-5672  |  Convallatoxin  |  Elacridar  |  RMS5  |  Laniquidar  |  Tenacissoside G  |  Evodine  |  Jatrophane 5  |  (R)-Verapamil hydrochloride  |  Valspodar  |  YHO-13351  |  Spongionellol A analog 1  |  ML230  |  3,7,2＇,4＇-Tetramethoxy-5-hydroxyflavone  |  Hypophyllanthin  |  Neostenine  |  EWP 815  |  Risperidone-d₄  |  P-gp inhibitor 14  |  Solamargine  |  P-gp modulator 2

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。